Ovid Therapeutics Inc. (FRA:1OT)

Market Cap	263.27M +814.6%
Revenue (ttm)	6.18M +1,181.3%
Net Income	-14.60M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	593
Open	2.080
Previous Close	2.040
Day's Range	2.080 - 2.080
52-Week Range	0.176 - 2.200
Beta	n/a
RSI	66.90
Earnings Date	May 13, 2026

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1OT

Financial Performance

In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.

Financial numbers in USD